We studied the surface expression of activation markers 
Eye (1992)6,643-647 involved. However, previous analyses of T-and B-cell subpopulations are largely reported to be unhelpful8 and general investigations of immune status yield little evi dence of significant functional defects in cellular immun ity.9 Recent reports of systemic T-cell activation,1O and the evidence of T-cell adhesion to retinal capillary endothelial cells, I I support the notion of systemic immunological acti vation leading to localised amplification of the immune system.
Therapeutic measures currently employed involve generalised immunosuppression and recently more speci fic immunomodulation with cyclosporin A.12-15 However, treatment is restricted by the side effects and resistance frequently observed with these therapies. Furthermore, relapses often occur on dose reduction as presently the only method of monitoring disease activity is by clinical assessment, which can be a poor representation of under lying immune activation.
In this study we examined 26 patients with idiopathic, endogenous uveoretinitis (both on and off treatment) to assess the degree of peripheral T-cell activation present and to identify possible systemic markers, if any, for moni toring disease activity and treatment response.
METHODS

Subject Group
Twenty-six patients with idiopathic posterior uveItis (unassociated with systemic disease, clinically or serolog ically) and 23 age-matched controls were studied in two groups described below ( Table I ). An additional 4 patients on cyclosporin A (CsA) therapy for treatment of retinal vasculitis were also studied by flow cytometric analysis. Patients were clinically graded on three separate compon ents -anterior segment, vitreal and fundal examinationas previously described.16,17 Controls had no clinical evi dence of intraocular inflammation and no evidence of systemic disease. Patients' lymphocyte markers were ana lysed by two methods: alkaline phosphatase anti-alkaline phosphatase (APAAP) analysis (group A) and flow cyto metric analysis (group B). 
APAAP Analysis
Peripheral blood (20 ml) was collected into acid--citrate dextrose(4: 1 v/v). This was diluted 1: 1 in sterile RPMI and layered onto Ficoll-Isopaque mixture (6 ml Ficol + 2.5 ml Isopaque, density 1.007 g/ml; Pharmacia, Uppsala, Sweden. Lymphoid cells collected from the interface were suspended in RPMI 10% fetal calf serum (FCS) at 5 x 105 ml and 100 III of the suspension was spun onto clean, degreased microscope slides at 10 000 r.p.m. for 5 min utes in a cytospin cytocentrifuge (Shandon Elliot, Chesh ire, UK). An APAAP technique for cell staining using a panel of primary monoclonal antibodies (Table II) was employed. Rabbit anti-mouse immunoglobulin (DAKO) was used as the secondary antibody and APAAP (mouse) complexes (DAKO) as the tertiary antibodies. The cells were counterstained with haematoxylin. To increase the sensitivity of the technique further incubation with the secondary and tertiary antibodies was performed with IL2-R and CD19 antibodies. The percentage of positively stained lymphocytes was counted from a grid of 200 cells. Full blood counts and differential white cell counts (Coul ter S plus profile) was also obtained. 
Flow Cytometry
Lymphocytes were collected and separated as described above and concentrated to 1 x 107/ml in RPMI 10% FCS. Flow cytometric analysis was performed using a single cell suspension through an EPICS C flow cytometer (Coulter Electronics, Luton, UK). Cell populations were studied using both single and dual immunofluorescence with fluorescein isothiocyanate (FITC) and phycoerythrin (PE) conjugates. Monoclonal antibodies (Table II) were prepared in 50 III volumes of phosphate-buffered saline (PBS) containing 5% heat-inactivated normal goat serum and 0.1 % sodium azide, and incubated with 50 III of mononuclear cells for 40 minutes. For dual fluorescence the cells were further incubated with secondary PE-conju gated antibodies in 5% normal goat serum and azide, then washed and resuspended in PBS. Background fluores cence was established with negative controls of PBS and monocyte markers (CD14-SAPU) and, in addition, for dual fluorescence positive controls of CD4+,CDI9+ were used. Results are given as mean surface marker expression. Adequate staining was assessed by the mean peak channel, after background was set.
Statistics
Mean surface marker expression was expressed ± SD, for both patients and controls in the two groups. Student's t-test was used and probability values of p<0.05 were found significant.
RESULTS
Both APAAP (n = 13) and flow cytometric (n = 13) analy sis of lymphocyte subsets demonstrated no significant difference in individual CD4, CD8 and B-cell populations between patients and controls. The CD4: CD8 ratio was significantly higher in the uveitis group of the APAAP study (patient = 2.3: 1 ± 1.3; control = 1.6: 1 ± 0.63; p<0.05), but this was not confirmed by flow cytometric analysis in the second group of patients. APAAP analysis of patients in group A (n = 13) and controls (n = 13) showed a significantly raised circulating lymphocyte (Fig. 1) .
Dual flow cytometric analysis confirmed a CD4+,IL2-R+ phenotype. (Fig. 2) . There was no increased expression on B-cells.
There was no significant correlation between disease activity (as established by the recently described uveitis grading systeml7 and either circulating HLA-DR or IL2-R expression. However, it must be emphasised that patients with active retinal vasculitis (n = 8) in the flow cytometric group, irrespective of extent of disease activity, demon strated a greater expression of IL2-R (Fig. 3) . Four patients with idiopathic retinal vasculitis who were treated with CsA demonstrated a 32% reduction in IL2-R expression after 3 months of treatment (Table IV) . .
. with foreign antigen expression are integral in the acti vation of the immune system. Expression of class II anti gens by lymphocytes is normally restricted to B-cells and occurs on activated T-cells only. Quiescent T-cells stimu lated by specific antigen by antigen presenting cells also express receptors for IL2 and will proliferate to autocrine or exogenous IL2. IL2-R expression is maintained only in the presence of IL2. The common leucocyte antigen CD45 R has three isoforms. CD45-RO cell surface expression occurs on maturation of naive to memory cells, as a signal of activation, and is thought to be a potential marker of activation in autoimmune disease. However, phenotype reversal to the common CD45-Ra phenotype is known to occur in mature memory cells, reducing the sensitivity of the marker. We have demonstrated systemic activation of circu lating T-Iymphocytes with increased levels of IL2-R expression, in two separate cohorts of patients by APAAP and flow cytometric techniques. The increase in expression of IL2-R by flow cytometry compared with APAAP may be explained by the larger cell sampling size and better staining characteristics employed by this tech nique. None of these patients had signs of systemic disease, either clinically or by standard laboratory testing (uveitis screen). We also observed increased HLA-DR expression in lymphocytes in group A patients studied by APAAP but not in group B patients studied by flow cytom etry. We believe this reflects differences in the sensitivity of the techniques used. APAAP detects both cytoplasmic and membrane expression, whilst flow cytometry
measures only cell surface fluorescence and the negative findings in flow cytometry are representative of the high background levels accounted for when the parameters are set. No difference was found in CD45-RO expression in either test, confirming the limited usefulness of this anti gen as a systemic marker of immune activation in organ specific autoimmune disease. Systemic T-cell activation in uveitis has been found in a previous study using flow cytometric analysis,1O but the sample group contained patients with systemic disease, in whom activation of cir culating T-cells might be expected from the underlying immunopathology of the disease processes. In our two cohorts of patients the treated and untreated patients were grouped together, which may have masked potential differences in activation marker expression.
This study, in accordance with others,S further demon strated that CD8 and CD4 levels are unhelpful parameters when assessing idiopathic uveitis. We could not confirm an abnormal CD4: CD8 ratio in uveitis patients with the two assays used.
In our second group of patients we demonstrated an increased IL2-R expression in patients with retinal vas culitis compared with other patients and controls. This increased expression, however, bore no significant corre lation with disease activity as assessed by a recently described uveitis scoring system. 17 An explanation of this may lie in the fact that the new uveitis scoring system details the extent of the disease but does not account for the severity of retinochoroidal inflammation. In this study we have observed that the more severe the retinal vas culitis, the greater the likelihood of identifying activated lymphocytes in the circulation. Recent work has demon strated activated T-cells in patients with systemic immune-mediated disease but not in idiopathic uveitis. I S Although there was no clinical evidence of systemic vas culitis in patients described in this study, further long-term follow-up will reveal whether these patients represent a subgroup of systemic vasculitic syndromes, a spectrum of disease that may present with predominant ocular signs, akin to sarcoid or Bechvet's disease. 19 It should be empha sised that dual flow cytometric analysis (Fig. 2) in this study confirmed the increased expression of the CD4+,IL2 -R+ phenotype, supporting the notion of a T-cell-mediated mechanism of the disease. 2 In a small subgroup of patients who were tested before and after commencing CsA therapy we observed a 32% reduction in IL2-R expression. This would be expected as an indirect consequence of the drug's action on the inhibi tion of IL2-mRNA20 and subsequent reduction in ampli fication of the T-cell response and IL2-R expression. CsA therapy, however, only partially reduced IL2-R levels, and further follow-up of these patients is required to assess whether the IL2-R becomes fully suppressed or whether IL2-R expression blockade by CsA is being circumvented by alternative pathways of T-cell activation. At present, the findings support the view that these observations represent real changes in the circulating T-cell phenotype with disease, and the corollary that this test may be used as a monitor of immunosuppression. We have not, however, longitudinally studied the effect of steroid therapy alone on activation marker expression.
We also studied peripheral lymphocyte expression of yo+ T-cell and CDS+ B(CD 19) cells. B-Iymphocytes expressing the T-cell-associated antigen CDS and T-cells bearing yo antigen receptor form only a minor population of the adult lymphoid pool, but are the major population in the neonatal lymphoid pool. Their functions are largely unknown, but are speculated as playing an important role in the development of self tolerance in the neonate and autoantibody formation and T-cell cytotoxicity at the site of inflammation in adults. 21, 22 Recent studies suggest that CDS+ B-cells act as a marker of activation, rather than an indicator of cells producing autoantibodies. 23 Although this phenotype is raised in the systemic circulation of other autoimmune diseases,24 we were unable to confirm a sig nificant rise in our group of patients. These cells, however, may still be generated locally, but again in such numbers that precludes identification by present tests.
The present and previous studies thus provide evidence for systemic T-Iymphocyte activation in idiopathic uveo retinitis and uveitis with concomitant systemic disease. The sensitivity and selectivity of present tests for auto reactivity do not permit accurate monitoring of antigen specific T-cells. The potential application of this study is still limited, however, by the inability to correlate acti vation marker expression with our present grading methods of clinical activity. There still remains a strong need for more accurate documentation and monitoring of the degree of immunosuppression during treatment.
Although only 4 patients were studied, we have demon strated that IL2-R expression may be an indicator not only of systemic activation but to active immunosuppression with CsA therapy in retinal vasculitis patients, the mech anism of which has been discussed. If the sensitivity of the above assays could be increased then the future appli cation of such monitoring would enhance the efficacy of present treatment modalities such as CsA and future immunotherapeutic measures that are also aimed at inhibi tion of secondary amplification of the immune response (cf. FKS06),z5
